CTXR - Citius Pharmaceuticals Inc. Price-to-Projected Revenue Ratio

Citius Pharmaceuticals (CTXR) faces a fierce patent battle in the critical care sector, where trial failures are critical. Meanwhile, operating within the US legal framework eliminates sanction risks. The forward P/S ratio, with a value fixed at 2.10, helps assess market valuation relative to expected sales. Citius Pharmaceuticals is pursuing the expansion of Lymphir oncology drugs to capture the hospital segment.

Citius Pharma - CTXR Projected Price to Revenue (period 02/14/2026 - 11/13/2026)

Comprehensive metric breakdowns and analytics for citiuspharma.com (CTXR)

- market price and analyst price targets:

Price Chart Citius Pharmaceuticals, Inc.|CTXR - Price Target Chart

- market capitalization statistics:

Market Value Citius Pharmaceuticals, Inc.|CTXR - Total Enterprise Value

- book value of equity indicators:

Book Value per Share Citius Pharmaceuticals|CTXR - Book Value of Business|Market Cap to Net Assets Ratio citiuspharma.com|CTXR - Company Assets

- debt and liquidity data:

Total Debt to Equity Ratio Citius Pharmaceuticals|CTXR - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Ratio Citius Pharmaceuticals, Inc.|CTXR - Company Cumulative Indebtedness|Debts to Book Capitalization Citius Pharmaceuticals, Inc.|CTXR - Company Long-Term Loans and Borrowings|Company Short-Term Debts Citius Pharmaceuticals|Quick Liquidity citiuspharma.com

- financial results and valuation multiples details:

CTXR - Final Profit|Projected Future Earnings Citius Pharmaceuticals|CTXR - P/E Multiple|Future Price to Earnings Citius Pharmaceuticals, Inc.|CTXR - Market Cap to Earnings and Growth Ratio|Enterprise Value to EBITDA Ratio Citius Pharmaceuticals, Inc.|CTXR - Profit before interest, taxes and amortization|Net earnings per share (EPS TTM) Citius Pharmaceuticals|CTXR - Net earnings per share for the last 12 months|Quarterly EPS earnings growth citiuspharma.com|CTXR - Expected net earnings per share growth this year|Expected earnings per share growth for next year Citius Pharmaceuticals

- revenue and sales proceeds data:

CTXR - Company Total Sales|Projected Sales Volume Citius Pharmaceuticals, Inc.|CTXR - Price-to-Revenue Coefficient|Forward Price-to-Revenue Multiple Citius Pharmaceuticals, Inc.

General company analysis:Citius Pharma CTXR

Manufactured products of Citius Pharmaceuticals Inc.

An investment audit of Citius Pharmaceuticals (CTXR) requires an analysis of the ratio between current market capitalization and projected revenue, which allows for an assessment of the value of each unit of future sales. For a biotech company with a narrow oncology portfolio, the expected P/S metric becomes a critical indicator reflecting the degree of market optimism priced in regarding the successful commercialization of drugs and the risks associated with dependence on clinical trial outcomes.

Key competitors

Price-to-Projected Revenue Ratio Incyte INCY|Hutchison MediPharma - Price-to-Projected Revenue Ratio|NUVB - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Day One Biopharmaceuticals Inc|MNPR: Forward P/S Multiple|Projected Price to Revenue inhibrx.com INBX|Forward Price-to-Revenue Multiple IMAB|Market Cap to Future Revenue Ratio Fennec Pharma FENC|Forward Price-to-Revenue Multiple HRTX (Heron Therapeutics)|NVCT (Nuvectis Pharma, Inc) - Forward Price to Sales|Coherus Biosciences - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio CRBP (corbuspharma.com)|Cardiff Oncology Corp - Forward P/S Multiple|Forward Price to Sales BYSI (BeyondSpring, Inc.)|BCAB: Forward P/S Multiple|Market Cap to Future Revenue Ratio Lixte Biotechnology, Inc. (LIXT)|Price-to-Projected Revenue Ratio Cellectar Biosciences|BLRX: Forward Price to Sales|Forward P/S Multiple CANF|Forward P/S Multiple aprea.com (APRE)|Price-to-Projected Revenue Ratio Kazia Therapeutics Limited KZIA|SLXN (Silexion Therapeutics Corp.) - Future Price to Revenue|NCNA: Forward Price-to-Revenue Multiple|Market Cap to Future Revenue Ratio chimerix.com|CYCC: Forward P/S Multiple|Forward Price-to-Revenue Multiple G1 Therapeutics|KRON (Kronos Bio Corp) - Forward P/S Multiple|Kintara Pharma (KTRA) - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple ONCT (Oncternal Therapeutics)|Price to Expected Revenue Ratio PRTG